Adenoid cystic carcinoma of the breast from a single-center cohort

Elizabeth Kander, Sania Raza, Sagar Dhamne, Mariana Solari, Sarika Jain*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Adenoid cystic carcinoma (ACC) of the breast is a rare breast tumor, comprising less than 1% of breast adenocarcinomas. Histopathologically, it is estrogen receptor (ER), progesterone receptor (PR), and HER2-negative (i.e., triple negative) but has a more indolent course than typical triple negative breast cancers. Most of what is known regarding ACC of the breast's treatment and prognosis is from case reports and case series. This case series reports a single institution's experience with ACC. Between 2003 and 2014, seven patients were found to have ACC of the breast. Most (6 of 7 cases) presented as a mammogram abnormality on routine screening. One patient was lost to follow up after initial diagnosis. All six patients underwent lumpectomy, sentinel lymph node biopsy (SLNB), and adjuvant radiation. None received systemic endocrine therapy or chemotherapy. All of the patients are without disease recurrence at median follow up of 6.2 years (range 0.4-10). Given the generally excellent prognosis of ACC of the breast and low tumor metastatic potential, it is reasonable to withhold adjuvant chemotherapy in the treatment of ACC and instead manage this malignancy with local therapy.

Original languageEnglish (US)
Pages (from-to)182-187
Number of pages6
JournalCancer Treatment Communications
Volume4
DOIs
StatePublished - Jan 1 2015

Keywords

  • Adenoid cystic carcinoma
  • Breast cancer
  • Triple negative

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Adenoid cystic carcinoma of the breast from a single-center cohort'. Together they form a unique fingerprint.

Cite this